110 completed, 12 terminated, 9 unknown, 9 withdrawn. 34 Phase 2, 34 Phase 3, 34 Phase 4, 16 Phase 1, 4 Not applicable.
Follow Interferon beta-1a: new trials by email Literature Review of Interferon beta-1a trials Research Report on Interferon beta-1a
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Early Interferon-beta Treatment for West-Nile Virus Infection Rebif 44 MCG Per 0.5 ML Prefilled Syringe, Saline - West Nile Virus, West Nile Fever Encephalitis | Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 100 | 2024-07-14 | 2024-07-23 |
| An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited) - Multiple Sclerosis (MS) | Active not recruiting | Bayer | 4 | 2024-03-20 | 2026-07-06 | |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis | Recruiting | Biogen | 908 | 2023-10-27 | 2026-08-11 | |
| Nivolumab in Children and Adults With Nasopharyngeal Carcinoma Nivolumab, Cisplatin, 5-Fluorouracil - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Recruiting | German Society for Pediatric Oncology and Hematology GPOH gGmbH | 57 | 2023-01-10 | 2024-05-16 |
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a - Multiple Sclerosis | Phase 2 | Unknown | German University in Cairo | 80 | 2022-02-01 | 2023-03-20 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments Remdesivir, Acalabrutinib, Interferon beta-1a - Covid19 | Phase 3 | Unknown | The University of The West Indies | 100 | 2021-06-01 | 2021-05-13 |
| the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19 | Phase 2 | Unknown | Shahid Beheshti University of Medical Sciences | 100 | 2020-08-20 | 2020-08-20 |
| Adaptive COVID-19 Treatment Trial 3 (ACTT-3) Interferon beta-1a, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 969 | 2020-08-05 | 2022-03-14 |
| Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic Convalescent Plasma Transfusion, Hydroxychloroquine, DAS181 - COVID-19 | Unknown | Qassim University | 200 | 2020-07-25 | 2020-07-07 | |
| Public Health Emergency: SOLIDARITY TRIAL Philippines Remdesivir, Hydroxychloroquine, Lopinavir / Ritonavir - Covid19 | Not applicable | Completed | University of the Philippines | 1314 | 2020-04-23 | 2022-03-02 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine - COVID-19 | Phase 4 | Unknown | Shahid Beheshti University of Medical Sciences | 40 | 2020-04-15 | 2020-04-20 |
| An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19 | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 60 | 2020-04-09 | 2020-05-05 |
| Trial of Treatments for COVID-19 in Hospitalized Adults Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A - Corona Virus Infection | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 1552 | 2020-03-22 | 2026-07-08 |
| Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products Interferon beta-1a, Peginterferon beta-1a, Placebo - Healthy Subjects, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 84 | 2020-02-28 | 2024-04-22 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis BIIB017 (peginterferon beta-1a), Interferon beta type 1a - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Active not recruiting | Biogen | 152 | 2019-10-18 | 2026-09-24 |
| Study of Evobrutinib in Participants With RMS Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 1 | 2019-09-10 | 2021-08-05 |
| Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) Evobrutinib, Avonex®, Avonex® matched Placebo - Relapsing-remitting Multiple Sclerosis | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 3 | 2019-08-26 | 2021-08-05 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
Showing 20 of 147. Sign in to see all of them.
Multiple Sclerosis (77) · Multiple Sclerosis, Relapsing-Remitting (53) · COVID-19 (9) · Recurrence (4) · Autoimmune Diseases (2) · Colitis, Ulcerative (2) · Demyelinating Diseases (2) · Inflammation (2) · Optic Neuritis (2) · Pneumonia (2) · Alzheimer Disease (1) · Asthma (1) · Autoimmune Diseases of the Nervous System (1) · Bone Diseases, Metabolic (1) · Burkitt Lymphoma (1)
Biogen (38) · Merck KGaA, Darmstadt, Germany (23) · EMD Serono (9) · Biocad (4) · Novartis Pharmaceuticals (4) · Sanofi (4) · Bayer (3) · EMD Serono Research & Development Institute, Inc. (3) · Genzyme, a Sanofi Company (3) · Shahid Beheshti University of Medical Sciences (3) · Teva Branded Pharmaceutical Products R&D, Inc. (3) · Celgene (2) · Centre Hospitalier Universitaire Vaudois (2) · Faron Pharmaceuticals Ltd (2) · Hoffmann-La Roche (2)
United States (61) · Germany (36) · United Kingdom (29) · Italy (28) · Canada (27) · Russia (25) · Spain (24) · France (23) · Czechia (20) · Poland (18) · Belgium (16) · Australia (15) · Finland (14) · Serbia (14) · Sweden (14)
Dr. Norbert Zessack (3) · Claudia Pena Rossi, M.D. (2) · Ilad Alavi Darazam, MD (2) · Ivan Sardaryan, PhD (2) · Minoosh Shabani, MD (2) · Mohammadreza Haji Esmaelie, MD (2)
PMID 30144037, PMID 34473343, PMID 34882037, PMID 36163349, PMID 36695483, PMID 37272540, PMID 37652990, PMID 22622860, PMID 27423899, PMID 27590291, PMID 28002679, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32511687, PMID 32690791, PMID 32710396, PMID 33414927, PMID 33724637, PMID 34035833, PMID 34350582, PMID 34904871, PMID 35672926, PMID 36619856, PMID 36792367, PMID 37148240, PMID 37745914, PMID 39290861, PMID 39935588, PMID 39965438, PMID 40258203, PMID 40462564, PMID 40554392, PMID 40629721, PMID 42832215, PMID 15714427, PMID 17654600, PMID 18071030, PMID 18789766, PMID 18946064, PMID 19145731, PMID 19302707, PMID 20542736, PMID 20659956, PMID 21397567, PMID 21742556, PMID 21960587, PMID 21988668, PMID 21999176, PMID 22047971
2014 (4), 2018 (3), 2009 (2), 2016 (2), 2023 (2), 2004 (1), 2005 (1), 2008 (1), 2015 (1), 2017 (1), 2019 (1), U01NS045719 (1)